|
SAGE cost-benefit calculations.
More on SAGE.
SAGE says:
"We recognise that cost-benefit analysis is an important tool for society in
determining the most effective use of resources, and in ensuring that society
does not devote so much resource to one issue that it results in more harm in
other areas than the benefit it creates. It is a way of assessing the
proportionality of any response to a health or safety issue."
The SAGE cost-benefit calculation proceeds as follows. We simply describe here
what SAGE has done, without commenting on whether it is right or not. SAGE
calculates the benefits first with reference to childhood leukaemia, then
considers how to extend it to other adverse health outcomes.
Assumptions about risk
To assess the benefit that reducing exposure might bring, it is necessary to
make an assumption about what the risk is.
SAGE makes two main assumptions.
-
It assumes that there actually is a risk for childhood leukaemia. That is, it
makes no allowance for the uncertainty in the scientific evidence.
-
It assumes that there is no risk below 0.4 µT but that there is a two-fold
increase in risk above 0.4 µT. This is derived mainly from the
Ahlbom pooled analysis
The normal risk of childhood leukaemia is 1 in 24,000 per year
more so the extra risk from the assumed doubling is also 1 in 24,000
per year.
On this basis, magnetic fields would cause
2 cases per year of childhood leukaemia in the UK. One of those cases
would be associated with power lines, and the other with a mixture of house
wiring and distribution wiring.
Benefits
Value to society of preventing a single case of childhood leukaemia
SAGE starts with a value used elsewhere in society (eg as recommended by HSE)
for the value of preventing a fatality: £1M per fatal case prevented
It then increases the value by a factor of 2 because childhood leukaemia is a
particularly unpleasant disease, and by another factor of 2 because it is
considering involuntary exposure to children: £4M per fatal cases prevented
For non-fatal cases, SAGE makes estimates of the serious impairment to the
child's quality and expectation of life, using figures advised by the National
Institute for Health and Clinical Excellence (NICE): £0.5M per non-fatal
case prevented
SAGE then assumes 30% of cases are fatal and 70% are not to give an overall
value to society: £1.6M per case prevented
Value to society of preventing one case per year of childhood leukaemia
SAGE follows Government advice to discount future benefits. It uses the
Government's figure of a discount rate of 3.5% per year for the first 30 years
and 3% after that. It also assumes the value society places on preventing cases
of disease increases by 2% per year. Finally, it considers a period of 50
years.
This gives: £50M per case per year prevented
Costs
SAGE applies its cost-benefit analysis to several of the options it considers,
but the main issue is around the "corridors" option, so that is the one we
consider here.
SAGE says there are two main financial costs of introducing "corridors" (SAGE
also lists non-financial consequences).
-
Land within the corridor that has not yet been developed but where there is an
expectation of future development loses value because that development cannot
now happen. SAGE estimates the cost of this as £1-2bn
-
Existing homes within the corridor or close to it may lose value as living near
a power line is seen as less desirable. SAGE considers this at length and
concludes there is a lot of uncertainty as to what the effect on property
values would be, but it estimates the cost of this as £0-2bn
In both cases, SAGE calculates the cost to society as a whole. In some cases,
the landowner or homeowner would receive compensation, in some cases they would
not, but SAGE just calculates the total cost.
Comparison of costs and benefits for childhood leukaemia
SAGE assumes that the entire future homebuilding programme near power lines,
which would otherwise take place but would be prevented if "corridors" were
introduced, would add between 50% and 100% to the number of homes already near
power lines. That is, under the assumptions that SAGE chose to make which
includes the assumption that magnetic fields actually do cause childhood
leukaemia, the "corridors" option would, in the fullness of time, prevent 0.5 -
1 case of childhood leukaemia per year.
Therefore, SAGE concludes:
Cost of introducing "corridors": £1-2bn
Benefit of introducing "corridors" (for childhood leukaemia): £25-50M
Health effects other than childhood leukaemia
SAGE also considers alternative assumptions, that magnetic fields might cause
adverse health effects other than childhood leukaemia. In this case, it says
the benefit "could be a hundred or so times larger".
Expressing these figures "per home"
The calculation so far has considered the total cost and the total benefit to
the UK. SAGE also presents the same calculation a different way, in terms of
the cost and benefit per home removed from the magnetic field.
For costs, the total figure of £1-4bn is to introduce corridors which would
prevent an estimated 25-50,000 homes being built. Therefore the cost per home
is £20k - £160k.
For the benefits, the calculated value to society is £50M for preventing one
case per year of childhood leukaemia. There is a 0.45 chance that a child lives
in any given home, and, on the SAGE assumptions, the risk they are removed from
when the house is removed from a field of 0.4 µT is 1 in 24,000 per year of
getting leukaemia. So the value to society per home removed from a field of 0.4
µT is £50M x 0.45 x (1/24,000) = £1k
Therefore SAGE presents the cost-benefit calculation for corridors as:
-
Cost per home removed from a field of 0.4 µT: £20k-160k
-
Health benefit per home removed from a field of 0.4 µT on the "WHO/HPA" view of
the science and assuming magnetic fields above 0.4 µT do cause childhood
leukaemia: £1k
-
Health benefit per home removed from a field of 0.4 µT on the "California" view
of the science: perhaps a hundred or so times larger
back
|